Spots Global Cancer Trial Database for Chronic Intestinal Pathologies Analytical Cohort at TouLouse

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Chronic Intestinal Pathologies Analytical Cohort at TouLouse

Official Title: Chronic Intestinal Pathologies Analytical Cohort at TouLouse

Study ID: NCT04896684

Conditions

Inflammatory Bowel Diseases

Colon Cancer

Interventions

blood and intestinal biopsy sampling

Study Description

Brief Summary: In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool will be studied. The aim of this project is to build a biological collection with associated clinical data for research projects.

Detailed Description: In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, two of them namely inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) will be more particularly studied. This interest is based on the increasing frequency of these two pathologies, their chronicities but above all the limited physiopathological data available. In addition, it seems interesting to study a third population, namely patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool. The study of this population is part of an improvement in knowledge on the carcinogenesis of colorectal cancer. To study these populations, blood, serum, plasma and tissues from colonous biopsies or surgical samples will be collected. This cohort will make it possible to study, among other things, the pathophysiology of chronic diseases of the small intestine and the colon (IBD, IBS, screening) in order to improve their management through the development of new biomarkers and therapeutic targets.